Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Chung Shan Medical University
  3. Pure學術人才庫轉入
  4. HER2 mutation profiling in mucinous ovarian carcinoma
 
  • Details
Options

HER2 mutation profiling in mucinous ovarian carcinoma

Other Title
Inferences for Enhertu (trastuzumab deruxtecan) as a potential therapeutic approach
Journal
Taiwanese Journal of Obstetrics and Gynecology
Date Issued
2025-09-01
Author(s)
HUANG-PIN SHEN  
YI-JU LEE  
DOI
10.1016/j.tjog.2025.04.013
URI
https://www.scopus.com/pages/publications/105012092422
https://scholars.csmu.edu.tw/handle/123456789/33272
Abstract
Objective: This study aimed to characterize HER2 mutations in Taiwanese mucinous ovarian carcinoma (mOC) and evaluate the potential of Enhertu (T-DXd) as a targeted therapy for HER2-mutant mOC. Materials and methods: We previously reported a 33.3 % (n = 7/21) HER2 tyrosine kinase domain (TKD) missense mutation rate in mOC using hot-spot PCR and Sanger sequencing. In this study, HER2 mutations were assessed in 18 additional mOC samples using targeted next-generation sequencing (NGS). Data from earlier PCR (n = 21) and current NGS (n = 18) were combined, resulting in all 39 cases. The COSMIC database and PolyPhen-2 (Polymorphism Phenotyping v2) algorithm were used to evaluate the pathogenicity of HER2 mutations identified in the NGS cohort. Results: HER2 mutations were detected in 43.6 % (n = 17/39) of cases. The PCR cohort (n = 21) from the previous 2 studies using PCR and Sanger sequencing identified seven TKD mutations. On the other hand, the NGS cohort (n = 18) from the present study using targeted NGS detected ten non-TKD mutations, with p.P1170A being the most frequent. PolyPhen-2 pathogenicity predictions indicated that p.P1170A and p.R143Q were likely pathogenic. Combining PCR and NGS data enhanced statistical power; however, the study was limited by the insufficient residual specimens from the PCR cohort for NGS reanalysis. Conclusion: Our findings reveal a high prevalence of HER2 mutations in mOC, with distinct profiles in TKD and non-TKD regions. These results support further investigation of Enhertu (T-DXd) as a promising targeted therapy for HER2-mutant mOC. Larger, multi-center studies are needed to validate these findings and explore clinical applications.
Type
journal article
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your Institution's web identity.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback